Single-chain antibodies as diagnostic tools and therapeutic agents

Journal:Thrombosis and Haemostasis
ISSN:0340-6245
DOI:http://dx.doi.org/10.1160/TH08-12-0816
Issue:2009: 101/6 (June) pp. 796-1180
Pages:1012-1019

Single-chain antibodies as diagnostic tools and therapeutic agents

Christoph E. Hagemeyer1; Constantin von zur Muhlen2; Dominik von Elverfeldt3; Karlheinz Peter1
1Atherothrombosis and Vascular Biology, Baker IDI Heart and Diabetes Institute, Melbourne, Victoria, Australia; 2Department of Cardiology and Angiology, University of Freiburg, Freiburg, Germany; 3Department of Radiology/Medical Physics, University of Freiburg, Freiburg, Germany

Summary

Over three decades after the generation of the first mouse monoclonal antibodies by Kohler and Milstein, recombinant antibodies are the fastest growing class of therapeutic proteins. Furthermore, antibodies are key detection reagents in research and diagnostics. Technology improvements have provided several approaches to manufacturing human antibodies with high affinity for biologically relevant targets. Approximately 300 development programs for therapeutic antibodies have been reported in industrial and academic laboratories, and this clearly demonstrates the expectations towards antibody technology. Antibody fragments are a subclass with growing clinical importance. This review focuses on single-chain antibodies as one of the smallest possible format for recombinant antibodies and their use as diagnostic tools and therapeutic agents. We describe the structure, selection and production of single-chain antibodies. Furthermore, we review current applications of antibody fragments focusing on thrombus targeting using fibrin- and plateletspecific single-chain antibodies as well as describing novel noninvasive imaging approaches for the diagnosis of thrombosis and inflammation.

Keywords

thrombosis, inflammation, imaging, Antibody fragments, phagedisplay

DOI

http://dx.doi.org/10.1160/TH08-12-0816

You may also be interested in...

1.

Paul Wexberg1, Nelli Jordanova2, Christoph Strehblow1, Bonni Syeda1, Brigitte Meyer1, Silvia Charvat1, Gerlinde Zorn1, Daniela Scheinig1, Johann Wojta1, Kurt Huber2, Dietmar Glogar1, Mariann Gyöngyösi

Thrombosis and Haemostasis 2008 99 4: 739-748

http://dx.doi.org/10.1160/TH07-05-0365

2.

Andrew J. Gale, Diana Rozenshteyn

Thrombosis and Haemostasis 2008 99 1: 44-51

http://dx.doi.org/10.1160/TH07-08-0495

3.

Peter K. Henke, Manu R. Varma, Daria K. Moaveni, Nicholas A. Dewyer, Andrea J. Moore, Erin M. Lynch, Christopher Longo, C. Barry Deatrick, Steven L. Kunkel, Gilbert R. Upchurch, Jr., Thomas W. Wakefield

Thrombosis and Haemostasis 2007 98 5: 1045-1055

http://dx.doi.org/10.1160/TH07-03-0190



Articles

You've 568 Article(s) in your Basket.

TH 107.5

Clinical Focus on GPIIb/IIIa inhibitors: In the May issue of Thrombosis and Haemostasis Armstrong...

TH 107.4

The April 2012 issue of Thrombosis and Haemostasis TH 107.4 is a Theme Issue by A. Schober, T....

Thrombosis and Haemostasis official organ of Spanish Society for Thrombosis and Haemostasis

Thrombosis and Haemostasis, founded in 1957, has become the official organ of the Spanish Society...